Business Context and Reporting Period
Prestige Brands Holdings, Inc. (Prestige) filed this Form 8-K on January 18, 2012, to report preliminary financial results for the third quarter and nine-month period ended December 31, 2011. The filing also discloses a proposed private offering of senior notes and new credit facilities to finance the acquisition of 17 over-the-counter (OTC) healthcare brands from GlaxoSmithKline plc (GSK).
Key Financial Metrics
Prestige Brands Holdings (Preliminary Results)
- Net Revenues (Q3 2011): Increased approximately 17% year-over-year.
- Net Revenues (9 Months 2011): Increased approximately 28% year-over-year.
- Gross Margin (Q3 2011): Increased approximately 16% year-over-year (excluding one-time items and acquisition costs).
- Gross Margin (9 Months 2011): Increased approximately 24% year-over-year.
- Contribution Margin (Q3 2011): Increased approximately 15% year-over-year (excluding one-time items and acquisition costs).
- Contribution Margin (9 Months 2011): Increased approximately 21% year-over-year.
- Liquidity (as of Dec 31, 2011): Cash and cash equivalents of $4 million.
- Debt (as of Dec 31, 2011): Total debt of $434 million.
GSK Brands (Historical Data for Proposed Acquisition)
- Revenue (9 Months Ended Sept 30, 2011): $156.9 million (down 0.4% vs. prior year).
- Gross Profit (9 Months Ended Sept 30, 2011): $107.0 million (down 2.5% vs. prior year); margin declined to 68.2% from 69.7%.
- Contribution Margin (9 Months Ended Sept 30, 2011): $78.3 million (down 3.6% vs. prior year); margin declined to 49.9% from 51.6%.
Material Changes vs. Prior Period
Prestige's revenue and margin growth in fiscal 2012 was primarily driven by the acquisitions of the Blacksmith Brands portfolio (including Efferdent, Effergrip, PediaCare, Luden's, and NasalCrom) and Dramamine, alongside organic growth in core OTC brands. Conversely, the GSK Brands portfolio showed slight revenue declines in the nine months ended September 30, 2011, driven by volume declines in FiberChoice, Beano, and Ecotrin, partially offset by growth in Gaviscon and Tagamet.
Guidance, Outlook, and Risks
Proposed Financing and Acquisition
- Notes Offering: Prestige intends to offer up to $290 million in senior notes due 2020.
- New Debt Facilities: Plans to enter into a $620 million seven-year term loan and a $50 million five-year asset-based revolving credit facility.
- Use of Proceeds: To finance the GSK Brands acquisition, repay existing senior secured credit facilities, and cover transaction fees.
- Existing Debt: Existing 8.25% Senior Notes due 2018 will be secured ratably with the new term loan.
Risks and Contingencies
- Unaudited Data: The preliminary financial results and pro forma information are unaudited and subject to change.
- Integration Risk: Actual results may differ from projections due to delays in completing the GSK acquisition or difficulties in integration.
- Market Conditions: Success depends on capital and debt market conditions and the ability to obtain financing on acceptable terms.
- Legal Matters: The GSK Brands are involved in various legal matters and product liability claims, though management believes these will not have a material adverse effect.
Investor Verification Checklist
- Verify the final audited financial statements for the quarter ended December 31, 2011, as current data is preliminary.
- Confirm the closing of the $290 million notes offering and the $620 million term loan facility.
- Monitor the regulatory approval and closing timeline for the GSK Brands acquisition.
- Review the unaudited pro forma combined financial information (Exhibit 99.2) for projected leverage and liquidity post-acquisition.
- Assess the impact of the FiberChoice brand impairment and declining revenue trends within the GSK portfolio on future synergies.